A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 1, 2008

Conditions

Leptomeningeal Carcinomatosis

Interventions

DRUG

RTA 744

Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston